# A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine

> **NCT03450915** · PHASE3 · COMPLETED · sponsor: **BiondVax Pharmaceuticals ltd.** · enrollment: 12460 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** M-001
- **BIOLOGICAL:** Saline

## Key facts

- **NCT ID:** NCT03450915
- **Lead sponsor:** BiondVax Pharmaceuticals ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-01
- **Primary completion:** 2020-07-02
- **Final completion:** 2020-10-23
- **Target enrollment:** 12460 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450915

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450915, "A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03450915. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*